http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102403453-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7024 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-742 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-742 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7024 |
| filingDate | 2018-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-102403453-B1 |
| titleOfInvention | Composition for the management of Helicobacter pylori infection |
| abstract | contain, individually or together, at least 10% w/w or more of 1-O-galloyl-β-D-glucose (β-glucogalin), for inhibiting the growth of Helicobacter pylori and managing infection thereof, and mucous acid 1,4-lactone 5-O-gallate, mucic acid 2-O-gallate, mucic acid 6-methyl ester 2-O-gallate (mucic acid 6-Methyl ester 2-O-gallate), mucic acid 1-methyl ester 2-O-gallate (mucic acid 1-Methyl ester 2-O-gallate) and ellagic acid (ellagic acid) acid) from about 10% w/w to greater than 60% w/w total mucic acid gallate, and the probiotic bacterium Bacillus A composition further comprising coagulance MTCC 5856 is disclosed. |
| priorityDate | 2017-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 49.